Cannabis for Cancer Declaration Seeks Partners for Cannabinoid Trials in Dogs

Organization encourages clinical cancer research following a 2026 systematic review supporting investigation of CBD's potential antitumor effects in dogs

BALTIMORE, MD, UNITED STATES, August 28, 2026 /EINPresswire.com/ -- Cannabis for Cancer Declaration, an advocacy initiative dedicated to advancing education and research into the potential anticancer applications of cannabis and cannabinoids, today announced an effort to identify veterinary oncology researchers and other partners interested in developing controlled clinical studies of cannabinoids in dogs with cancer.

The organization intends to explore ways to help qualified researchers move promising cannabinoid research toward clinical investigation. Potential support could include financial assistance where feasible, research and literature support, public and pet-owner outreach, assistance identifying additional collaborators, and connections with organizations interested in advancing veterinary cannabinoid research.

The announcement follows the May 21, 2026 publication of a systematic review in *Frontiers in Veterinary Science* titled **"Potential antitumor effect of cannabidiol (CBD) in canine oncology: a systematic review."**

The review examined eight preclinical studies involving canine cancers, including lymphoma, mammary cancer, glioma, prostate cancer, osteosarcoma and urothelial carcinoma. The authors reported that the studies consistently found antiproliferative and pro-apoptotic effects from CBD and concluded that the existing findings support clinical trials investigating its pharmacology and potential antitumor efficacy in dogs with cancer.

"The goal of this initiative is to advance rigorous clinical studies that can determine whether cannabinoids improve outcomes in dogs with cancer," said Justin Kander, founder of Cannabis for Cancer Declaration. "The preclinical evidence has reached a point where answering those questions in appropriately designed clinical research is warranted."

Although the May 2026 systematic review focused primarily on CBD, Cannabis for Cancer Declaration is interested in research evaluating CBD and other cannabinoids or cannabinoid formulations where supported by scientific evidence and appropriate veterinary oversight.

Research in dogs may also have implications beyond veterinary medicine. The National Cancer Institute has an established Comparative Oncology Program based on the scientific value of studying naturally occurring cancers in pet dogs. According to the NCI, dogs and humans share important similarities in their genomes, immune responses, environments and tumor complexity, making canine cancer research potentially valuable to the development of future treatments for both species.

A separate randomized, placebo-controlled clinical study involving dogs with lymphoma has also demonstrated that CBD/CBDA-rich hemp oil can be studied prospectively in canine cancer patients receiving chemotherapy. That study, published in 2025, focused on safety, tolerability and interactions with CHOP chemotherapy rather than determining whether cannabinoids themselves exert anticancer effects.

Cannabis for Cancer Declaration believes controlled efficacy trials are a logical next step.

"Veterinary oncologists and researchers are in the best position to determine what these studies should look like," Kander said. "Cannabis for Cancer Declaration wants to find investigators who see scientific merit in this question and determine how we can help them pursue it."

The organization is seeking contact with veterinary oncologists, veterinary schools, academic researchers, research institutions, animal cancer organizations, funders and other qualified parties interested in discussing potential clinical research.

Cannabis for Cancer Declaration emphasizes that preclinical research and anecdotal reports do not establish cannabinoids as effective cancer treatments in dogs. Any future clinical research should be conducted with appropriate veterinary and institutional oversight, standardized products and careful attention to dosing, safety, drug interactions and animal welfare.

About Cannabis for Cancer Declaration

Cannabis for Cancer Declaration is an advocacy initiative dedicated to advancing education and research into the potential role of cannabis and cannabinoids in cancer treatment. The organization promotes public education, scientific inquiry, patient-centered advocacy and rigorous clinical investigation into whether cannabinoids can directly affect cancer and how they may be used safely and effectively.

Media Contact
Justin Kander
Cannabis for Cancer Declaration
CannabisDeclaration.com
410-967-1832

Justin Kander
Cannabis for Cancer Declaration
+1 410-967-1832
info@cannabisdeclaration.com
Visit us on social media:
Instagram